155 related articles for article (PubMed ID: 35259193)
21. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
22. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Brechbuhl HM; Vinod-Paul K; Gillen AE; Kopin EG; Gibney K; Elias AD; Hayashi M; Sartorius CA; Kabos P
Mol Carcinog; 2020 Oct; 59(10):1129-1139. PubMed ID: 32822091
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.
Rizzo FM; Vesely C; Childs A; Marafioti T; Khan MS; Mandair D; Cives M; Ensell L; Lowe H; Akarca AU; Luong T; Caplin M; Toumpanakis C; Krell D; Thirlwell C; Silvestris F; Hartley JA; Meyer T
Br J Cancer; 2019 Feb; 120(3):294-300. PubMed ID: 30636773
[TBL] [Abstract][Full Text] [Related]
24. Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients.
Zhu P; Liu HY; Liu FC; Gu FM; Yuan SX; Huang J; Pan ZY; Wang WJ
Cancer Control; 2021; 28():10732748211027163. PubMed ID: 34378430
[TBL] [Abstract][Full Text] [Related]
25. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
Klusa D; Lohaus F; Franken A; Baumbach M; Cojoc M; Dowling P; Linge A; Offermann A; Löck S; Hušman D; Rivandi M; Polzer B; Freytag V; Lange T; Neubauer H; Kücken M; Perner S; Hölscher T; Dubrovska A; Krause M; Kurth I; Baumann M; Peitzsch C
Int J Cancer; 2023 Jun; 152(12):2639-2654. PubMed ID: 36733230
[TBL] [Abstract][Full Text] [Related]
26. Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1.
Tang Y; Lu Y; Chen Y; Luo L; Cai L; Peng B; Huang W; Liao H; Zhao L; Pan M
J Exp Clin Cancer Res; 2019 Nov; 38(1):473. PubMed ID: 31752959
[TBL] [Abstract][Full Text] [Related]
27. Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Kędra B; Mroczko B
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867211
[TBL] [Abstract][Full Text] [Related]
28. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
30. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.
Morita T; Kodama Y; Shiokawa M; Kuriyama K; Marui S; Kuwada T; Sogabe Y; Matsumori T; Kakiuchi N; Tomono T; Mima A; Ueda T; Tsuda M; Yamauchi Y; Nishikawa Y; Sakuma Y; Ota Y; Maruno T; Uza N; Nagasawa T; Chiba T; Seno H
Cancer Res; 2020 Oct; 80(19):4058-4070. PubMed ID: 32606001
[TBL] [Abstract][Full Text] [Related]
32. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
33. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response.
Pore AA; Dhanasekara CS; Navaid HB; Vanapalli SA; Rahman RL
Bioengineering (Basel); 2023 Apr; 10(4):. PubMed ID: 37106672
[TBL] [Abstract][Full Text] [Related]
35. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
36. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
38. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
39. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
[TBL] [Abstract][Full Text] [Related]
40. Circulating Hepatocellular Carcinoma Cells are Characterized by CXCR4 and MMP26.
Yu C; Wang Z; Xu X; Xiang W; Huang X
Cell Physiol Biochem; 2015; 36(6):2393-402. PubMed ID: 26279442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
